Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Investor Presentation (July 2021)
23 slides from Genetic Technologies's investor presentation, Jul 28, 2021
Slide 1: Genetic Technologies Investor Update July 2021
Genetic Technologies Investor Update July 2021 Authorised by the Board of Directors of Genetic Technologies Limited ASX: GTG NASDAQ: GENE
Slide 2: Notice: Forward looking statements
Notice: Forward looking statements The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require fu
Slide 3: Our Overview
geneType CO, Our Overview 01; 02| 03; 04; 05; 06 Our Vision & Our Markets Our Channels Our Portfolio & Our Acquisition ur Capabilities Values & Divisions Innovation aa racial iucrmsing the Focusedion:tiines Executing through = EasyDNA- Building fea market entry distinct and target cutting edge innov
Slide 4: Our Vision & Values
Our Vision & Values To be the world’s leader in personalised predictive genetics Collaborative Cooperative, Receptive, Informative, Transparent Unity and diversity drives us to make a positive impact on the community Professional Trustworthy, Respectful, Punctual, Accountable Leveraging our collecti
Slide 5: Our 2021 Snapshot
Our 2021 Snapshot Mul year distribution agreement A$21 million Strong cash balance with 24 month runway? License and distribution agreement for COVID- 19 Risk Test with IBX for minimum of US$2.9 million over 3 years to maintain exclusivity Launched CIT in USA & AUS for other tests' Strong focus on C
Slide 6: Our Markets and Collaborators
Our Markets and Collaborators United States geneType® Polygenic Risk Score (PRS) tests for breast, and CO! through “High Compl Laboratories. Further products expected to be submitted in next 12 months =] THE UNIVERSITY OF 9, MELBOURNE Europe & UK Commencing CE certification enabling EU launch of Nov
Slide 7: Medical — Business to Business
Medical — Business to Business (B2B) A communication Certifying and execution reimbursable plan curated for germline testing platform Payers / Insurers BRCA test Primary Care Physicians LYNCH Syndrome test Specialists (More to follow)" Surgeons Allied Health * Corporates and Insurance market entry a
Slide 8: Our Channels — B2B
geneType CO, Our Channels — B2B Business to business sales via the ~~ medical profession Third Party Licensing 4 + Adversely impacted by COVID-19 restrictions but remains a key avenue for education and = Provides enhanced distribution and product ~~ sales onetingivia: SS + Combined with an education
Slide 9: Our Divisions
Our Divisions @ Emerging divisions Pharmoco- Genetics & Companion diagnostics Oncology BC, CRC, PC, Melanoma NEW - Universal collection test Kit To support Multi Test Launch @ Existing divisions ermline testing BRCA, Lynch Syndrome and jomatic testing; cvD (Heart Disease) e IHD, AF I geneType « © Ge
Slide 10: Our Innovation
Our Innovation geneType integrates genetic risk and clinical risk to better stratify individual risk. Patients with potentially high risk may exceed actionable clinical guidelines 10 — 15 years earlier than those with low risk 1:25 Breast Cancer (BC)' Colorectal Cancer (CRC)? Chronic Heart Disease (
Slide 11: Our Portfolio - Driving Growth
S. Greener ww Our Portfolio - ~ Driving Growth CIT Platform in AUS Moderate and USA selling BRC Revenue and CRC Expectation Q2 cy 2021 rs IBX COVID Risk Test [MiReimm ri Revenue released for sale May aa . sbx Commence 31, 2021 Sioa thay Meee " -_ Q2 CY 2021 100% Germline + Expanding into reimbursabl
Slide 12: Significant market opportunity
ww Significant market opportunity To provide predictive, pre-symptomatic testing to inform lifestyle choices and healthcare discussio| . . ‘Near term Addressable Market TG Target M; BRCA Panel + Breast Cancer PR: 281,550: ie degree g- = Testing g- = = providing up to 100% genetic risk cover screenin
Slide 13: Our Innovation - Multi Test
Our Innovation - Multi Test One test to help identify risk of serious disease for up to 70% of Mortalities and Morbidities Committed to continually invest in developing multi population testing solutions Oncology GeneType Multi-test to include B G) >70% of mortality & morbidity east Cancer @ Colorec
Slide 14: EasyDNA — Acquisition of DTC Platform
EasyDNA — Acquisition of DTC Platform = easyDNA This acquisition provides Genetic Technologies the foundation to grow in 40 countries with an extensive DTC market channel Agreements with 12 laboratories in North America, AsiaPac and Europe EasyDNA currently sells paternity, oncology and health and w
Slide 15: Our Capability
Our Capability infrastructure for a direct to consumer e-commerce and B28 sales platform Marketing and Positioning © Creating a consumer and patient led fy \ \ Commercial Finance Innovation underpinned by -ontrolled operating expenditure nhanced IT infrastructure Futureproofing our platform Dedicate
Slide 16: Our Summary
Our Summary 01; 02| 03; 04; 05; 06 Our Vision Our Markets Our Channels Our Portfolio & Our Acquisition ur Capabilities and Values & Divisions Innovation Targeted and Focused and Cutting edge Positioned for Aligned Cobras distinct innovation growth
Slide 17: Thank you
Thank you CQ,
Slide 18: Appendices
Appendices
Slide 19: Our Intellectual Property Patents granted in the US
Our Intellectual Property 7 Patents granted in the US + Patent 11,031,098, Computer systems and methods for genomic analysis + Patent 10,683,549, Methods for assessing risk of developing breast cancer + Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three of the core genetic markers include
Slide 20: Board and Management
Board and Management: Sales and Scientific expertise leading GTG Mr. Peter Rubinstein BEc, LLB Chairman - Non — Executive Director Simon Morriss GAICD Chief Executive Officer Richard Allman BSc, PhD Chief Scientific Officer Dr. Lindsay Wakefield MBBS Non — Executive Director Dr. Jerzy “George” Muchn
Slide 21: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board ® 8 Professor Jon Emery MBBCh MA DPhil FRACGP MRCGP Research & Education Lead, Primary Care Integration, Victorian Comprehensive Cancer Centre Herman Chair of Primary Care Cancer Research, University of Melbourne Professor Finlay Macrae AO MBBS, MD, FRACP
Slide 22: Corporate Overview
2 genetyee ww . Corporate Overview Top 50 share registry breakdown Dual Listed on the ASX and Nasdaq Financial Information Other, 21% Share price (AUD) as at 26 July 2021 0.8¢ ADR price (USD) as at 26 July 2021 $3.66 Ord Share on Issue (M) 9,017 ASX 52-week trading (low/high) 0.6/1.4c Nasdaq 52-week
Slide 23: Defined Terms
geneType Defined Terms Common Complex Diseases (CCP) — A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease Polygenic risk score - a number ass
Genetic Technologies — Investor Presentation (July 2021) on 6ix